Immunity challenge

Rybka, Ted
June 2005
Echo Magazine;6/2/2005, Vol. 16 Issue 19, p53
Interviews Doctor Jon Kaiser about AIDS. Effectiveness of his HIV/AIDS treatment plan; Changes in the development and treatment of HIV and AIDS; Views on the efficiency of the combination of vitamin supplements and antiviral therapy in treating HIV and AIDS.


Related Articles

  • HIV: FROM DEATH SENTENCE TO CHRONIC DISEASE. Karpa, Kelly Dowhower // Drug Topics;10/6/2003, Vol. 147 Issue 19, p72 

    Focuses on antivirals and updated guidelines that offer new opportunities for pharmaceutical management of AIDS in the 21st century. Impact of combination therapy on HIV morbidity and mortality; Preferred antiretroviral drug regimens; Potential benefits of early therapy initiation; Risks of...

  • News.  // Clinical Infectious Diseases;9/15/2001, Vol. 33 Issue 6, p1 

    Presents an update on infectious diseases as of September 2001. Information on the vote against the approval of Aviron Incorporated's FluMist flu vaccine in the United States; Launch of a program to reduce the spread of HIV through tainted blood transfusions in China; Introduction of a 3-in-1...

  • Strategies for Inhibiting Function of HIV-1 Accessory Proteins: A Necessary Route to AIDS Therapy? Richter, S. N.; Frasson, I.; Pal´┐Ż, G. // Current Medicinal Chemistry;Jan2009, Vol. 16 Issue 2, p267 

    The Human Immunodeficiency Virus (HIV) genome encodes three major structural proteins common to all retroviruses (Gag, Pol and Env), two regulatory proteins (Tat and Rev) that are essential for viral replication, and four accessory proteins (Nef, Vif, Vpu, Vpr). While accessory proteins were...

  • New Therapies in HIV/AIDS Treatment. Garmany, Justin; Kramer, Richard // Drug Formulary Review;Jun2008 Supplement, Vol. 24, p1 

    The article focuses on the developments in therapies for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). It emphasizes the positive effect of highly reactive antiretro-viral therapy (HAART) on the quality of life, T cell count and survival in HIV patients. The...

  • HIV Antiretroviral Drug Resistance. Campo, Jose E.; Jamjian, Christine; Goulston, Claudia // Journal of AIDS & Clinical Research;Special2012, Vol. 3 Issue S, Special section p1 

    The article describes some of the challenges in the use of highly active antiretroviral therapy (HAART) from the perspective of HIV resistance. It defines drug resistance in HIV as a reduced susceptibility to a specific antiretroviral (ARV) and has been documented since the introduction of ARV...

  • The Abandoned Trials of Pre-Exposure Prophylaxis for HIV: What Went Wrong? Singh, Jerome A.; Mills, Edward J. // PLoS Medicine;Sep2005, Vol. 2 Issue 9, p824 

    Discusses the impact of irresponsible reporting and activism against the use of the oral antiretroviral drug tenofovir as a pre-exposure prophylaxis (PREP) for HIV/AIDS. Protests against trials of PREP; Concerns of the protestors; Threats to PREP trials.

  • HIV: NOW AND THEN.  // Gay Times (09506101);Feb2013, Issue 415, p115 

    The article offers reflections on the pre- and post-human immunodeficiency virus (HIV) antiretroviral generations. One respondent views that alternative therapies give pleasure to people with HIV even if they may not have any direct effect on the virus itself. Another respondent considers...

  • Effect of Immunomodulating Adjuvant Dzherelo (Immunoxel) in HIV Infected Patients Receiving Standard Antiretroviral Therapy. Nikolaeva, Lyudmila G.; Maystat, Tatiana V.; Volyanskii, Yuri L.; Pylypchuk, Volodymyr S.; Frolov, Valery M.; Kutsyna, Galyna A. // Open Virology Journal;2009, Vol. 3, p31 

    Open-label, matched-case, comparative trial was conducted in 40 HIV-infected patients to evaluate the adjunct effect of Dzherelo (Immunoxel) on immune and viral parameters. Arm A (n=20) received anti-retroviral therapy (ART) consisting of zidovudine, lamivudine, and efavirenz and arm B (n=20)...

  • HIV-1 Protease: Structural Perspectives on Drug Resistance. Weber, Irene T.; Agniswamy, Johnson // Viruses (1999-4915);Dec2009, Vol. 1 Issue 3, p1110 

    Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have dramatically improved AIDS therapy. Analysis of the structures and activities of drug resistant protease variants has revealed novel molecular mechanisms of drug resistance and guided the design...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics